Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

589 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Linch DC, Yung L, Smith P, Maclennan K, Jack A, Hancock B, Cunningham D, Hoskin P, Qian W, Holte H, Boesen AM, Grigg A, Browett P, Trneny M. Linch DC, et al. Among authors: hancock b. Br J Haematol. 2010 Apr;149(2):237-43. doi: 10.1111/j.1365-2141.2010.08081.x. Epub 2010 Mar 1. Br J Haematol. 2010. PMID: 20201949 Free article. Clinical Trial.
Risk of premature menopause after treatment for Hodgkin's lymphoma.
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A, Hoskin PJ, Linch DC, Lister A, Lucraft HH, Radford J, Stevens AM, Syndikus I, Williams MV; England and Wales Hodgkin Lymphoma Follow-up Group. Swerdlow AJ, et al. J Natl Cancer Inst. 2014 Aug 19;106(9):dju207. doi: 10.1093/jnci/dju207. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25139687
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC. Harrison CN, et al. Among authors: hancock b. Br J Cancer. 1999 Oct;81(3):476-83. doi: 10.1038/sj.bjc.6690718. Br J Cancer. 1999. PMID: 10507773 Free PMC article.
ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC; British National Lymphoma Investigation; Central Lymphoma Group. Hancock BW, et al. Br J Cancer. 2001 May 18;84(10):1293-300. doi: 10.1054/bjoc.2001.1778. Br J Cancer. 2001. PMID: 11355937 Free PMC article. Clinical Trial.
Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, Marcus RE, Jelliffe A, Vaughan G, Hudson, Linch DC; British National Lymphoma Investigation. Ardeshna KM, et al. Among authors: hancock bw. Lancet. 2003 Aug 16;362(9383):516-22. doi: 10.1016/s0140-6736(03)14110-4. Lancet. 2003. PMID: 12932382 Clinical Trial.
589 results